Pharma and biologics manufacturers will soon have big decisions to make regarding their pharmaceutical and biological product strategy in Canada. On September 6, 2017, the Governor General in Council, on recommendation of the...more
The patent litigation that propels generic and biosimilar products to market will soon change dramatically. July 15, 2017, marked the release of long-awaited proposed amendments to the Patented Medicines (Notice of...more
On June 9, 2015, the Canadian Competition Bureau released updated draft Intellectual Property Enforcement Guidelines (IPEGs) for public comment. The comment period is open until August 10, 2015. It is the third publication of...more
6/15/2015
/ Antitrust Provisions ,
Canada ,
Competition Act ,
Competition Authorities ,
Federal Trade Commission (FTC) ,
Generic Drugs ,
Intellectual Property Protection ,
Patent Assertion Entities ,
Patents ,
Pharmaceutical Industry ,
Standard Essential Patents